Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference...
June 01 2018 - 8:00AM
Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on
novel therapies in oncology, today announced that the company will
host an event featuring key opinion leaders in the cancer
immunotherapy landscape on Monday, June 4, 2018 at 6:45 a.m.
Central Time in Chicago.
In addition, Carlos Paya, M.D., Ph.D., President and Chief
Executive Officer, will present at the Jefferies 2018 Global
Healthcare Conference in New York on Wednesday, June 6, 2018 at 3
p.m. ET.
The June 4 event will feature a discussion of the cancer
immunotherapy landscape and Immune Design’s approaches and clinical
programs in sarcoma and follicular lymphoma. Presenters will
include Immune Design’s management team and guest speakers:
- Carl H. June, M.D., Director, Parker Institute for Cancer
Immunotherapy, Perelman School of Medicine, University of
Pennsylvania
- Jean-Yves Blay, M.D., Director, Centre Léon Bérard,
Comprehensive Cancer Center of Lyon and the Rhône-Alpes
region
- Christopher R. Flowers, M.D., M.S., Director, Lymphoma Program,
Winship Cancer Institute, Emory University
A live webcast of each presentation will be available online
from the investor relations page of the company's corporate website
at http://ir.immunedesign.com/events-and-presentations.
After the live webcast, an archive of the presentation will
be available on the company website for 30 days.
About Immune Design
Immune Design is a late-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic immune cells to
fight cancer and other chronic diseases. CMB305 and G100, the
leading product candidates with broad potential in oncology, are
based on the company’s two technology platforms that are potent
stimulators of the immune system: ZVex® and GLAAS®. Both ZVex
and GLAAS also have potential applications in infectious disease
and allergy indications, which are being developed through ongoing
pharmaceutical collaborations. Immune Design has offices in
Seattle and South San Francisco. For more information, please visit
www.immunedesign.com.
Media ContactJulie
Rathbunjulie.rathbun@immunedesign.com206-769-9219
Investor ContactSylvia
WheelerSylvia.wheeler@immunedesign.com
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Sep 2023 to Sep 2024